ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Gilead Sciences, GlaxoSmithKline and Hoffmann-La Roche side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Gilead Sciences×GlaxoSmithKline×Hoffmann-La Roche×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Gilead SciencesGlaxoSmithKlineHoffmann-La Roche
studies on the registry7394,1982,744
open to participants now33135114
phase 3 studies under way337695
reach primary completion within a year196676
programswith a study of their own in two years3288+17 named only80+25 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGilead SciencesGlaxoSmithKlineHoffmann-La Roche
Phase 1

Gilead Sciences: 6 of its 32 programs at phase 1

  1. GS-0151phase 1
  2. GS-0415phase 1
  3. GS-1206phase 1
  4. GS-2426phase 1
  5. GS-5319phase 1

and 1 more — sign in to see them all

19%

GlaxoSmithKline: 19 of its 88 programs at phase 1

  1. Pn-MAPS30plusphase 1
  2. GSK4771261phase 1
  3. Antibody-drug Conjugate GSK5533524phase 1
  4. ganfeborolephase 1
  5. GSK4425689Aphase 1

and 14 more — sign in to see them all

22%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%
Phase 2

Gilead Sciences: 6 of its 32 programs at phase 2

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2
  2. denikitugphase 2
  3. GS-1179phase 2
  4. GS-4321phase 2
  5. PTM Cilofexor Dose Aphase 2

and 1 more — sign in to see them all

19%

GlaxoSmithKline: 36 of its 88 programs at phase 2

  1. dezecapavirphase 2
  2. nelistotugphase 2
  3. GSK3862995Bphase 2
  4. VH4524184phase 2
  5. nirogacestatphase 2

and 31 more — sign in to see them all

41%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%
Phase 3

Gilead Sciences: 15 of its 32 programs at phase 3

  1. anitocabtagene autoleucelphase 3
  2. domvanalimabphase 3
  3. teropavimabphase 3
  4. zinlirvimabphase 3
  5. seladelparphase 3

and 10 more — sign in to see them all

47%

GlaxoSmithKline: 23 of its 88 programs at phase 3

  1. belantamab mafodotinphase 3
  2. felcorekibartphase 3
  3. risvutatug rezetecanphase 3
  4. velzatinibphase 3
  5. efimosfermin alfaphase 3

and 18 more — sign in to see them all

26%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

Gilead Sciences: 5 of its 32 programs at approved, new studies

  1. sacituzumab govitecanapproved, new study
  2. lenacapavirapproved, new study
  3. tenofovir alafenamideapproved, new study
  4. bictegravirapproved, new study
  5. Emtricitabineapproved, new study
16%

GlaxoSmithKline: 10 of its 88 programs at approved, new studies

  1. dostarlimabapproved, new study
  2. cabotegravirapproved, new study
  3. depemokimabapproved, new study
  4. belimumabapproved, new study
  5. niraparibapproved, new study

and 5 more — sign in to see them all

11%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Gilead Sciences10 readouts · 2 phase 3·

Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion

  1. anitocabtagene autoleucelphase 3 · Dec 0 · NCT05396885
  2. sacituzumab govitecanapproved, new study · Dec 0 · NCT04617522
··

Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion

  1. domvanalimabphase 3 · Mar 0 · NCT06727565
  2. GS-0151phase 1 · Mar 0 · NCT06902519
  3. lenacapavirapproved, new study · Mar 0 · NCT06749054
  4. Optimized Background Regimen (OBR)phase 3 · Mar 0 · NCT06749054
··

Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. Emtricitabineapproved, new study · Jun 0 · NCT06337032
  2. tenofovir alafenamideapproved, new study · Jun 0 · NCT06337032
·

Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion

  1. bictegravirapproved, new study · Aug 0 · NCT07645287
  2. GS-3242phase 3 · Aug 0 · NCT07645287
··
GlaxoSmithKline40 readouts · 8 phase 3

GlaxoSmithKline, Nov ’26: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. dostarlimabapproved, new study · Nov 23 · NCT06567782
  2. Pentetic Acidphase 3 · Nov 23 · NCT07596199
  3. niraparibapproved, new study · Nov 26 · NCT03981796

GlaxoSmithKline, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccinephase 1 · Dec 3 · NCT07464314
  2. momelotinibphase 3 · Dec 11 · NCT03441113
  3. GSK3862995Bphase 2 · Dec 16 · NCT06154837
  4. HFA-152aphase 3 · Dec 28 · NCT07645248
  5. norfluranephase 3 · Dec 28 · NCT07645248

and 1 more — sign in to see them all

GlaxoSmithKline, Jan ’27: 4 programs whose next study reaches primary completion

  1. Adjuvanted RSVPreF3 vaccinephase 2 · Jan 12 · NCT07092865
  2. velzatinibphase 3 · Jan 12 · NCT07862114
  3. SOC INSTI-based ARTphase 1 · Jan 22 · NCT07053384
  4. VH3810109phase 2 · Jan 22 · NCT07053384

GlaxoSmithKline, Feb ’27: 2 programs whose next study reaches primary completion

  1. dezecapavirphase 2 · Feb 18 · NCT07934719
  2. Pn-MAPS30plusphase 1 · Feb 22 · NCT07406334

GlaxoSmithKline, Mar ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. depemokimabapproved, new study · Mar 1 · NCT07671001
  2. CAB ULAphase 3 · Mar 8 · NCT06786520
  3. cabotegravirapproved, new study · Mar 8 · NCT06786520
  4. camlipixantphase 3 · Mar 9 · NCT07519395
  5. ozureprubartphase 2 · Mar 16 · NCT07220811

and 1 more — sign in to see them all

GlaxoSmithKline, Apr ’27: 2 programs whose next study reaches primary completion

  1. felcorekibartphase 3 · Apr 13 · NCT07712393
  2. as01ephase 2 · Apr 23 · NCT07036159

GlaxoSmithKline, May ’27: 5 programs whose next study reaches primary completion

  1. Candidate UTI vaccine HTD formulation 2phase 2 · May 3 · NCT06702449
  2. Candidate UTI vaccine low dose formulation 1phase 2 · May 3 · NCT06702449
  3. VH4770359phase 1 · May 5 · NCT07525544
  4. gepotidacinphase 3 · May 17 · NCT07645235
  5. GSK4771261phase 1 · May 20 · NCT07600450

GlaxoSmithKline, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Bevacizumabphase 2 · Jun 21 · NCT06796907
  2. belimumabapproved, new study · Jun 29 · NCT06411249
  3. Low dose Strep A Alumphase 1 · Jun 29 · NCT07085702
  4. Low dose Strep A AS37phase 1 · Jun 29 · NCT07085702

GlaxoSmithKline, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mRNA Seasonal Flu vaccinephase 3 · Jul 9 · NCT07851246

GlaxoSmithKline, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. belantamabphase 2 · Aug 5 · NCT07742527
  2. shingrixapproved, new study · Aug 23 · NCT05371080

GlaxoSmithKline, Sep ’27: 1 program whose next study reaches primary completion

  1. mocertatug rezetecanphase 3 · Sep 22 · NCT06431594

GlaxoSmithKline, Oct ’27: 4 programs whose next study reaches primary completion

  1. GSK3772701phase 2 · Oct 8 · NCT07545681
  2. efimosfermin alfaphase 3 · Oct 13 · NCT07358546
  3. Anti-PSMA/Anti-CD3 T-cell Engager GSK5458514phase 2 · Oct 26 · NCT06990880
  4. VH4524184phase 2 · Oct 28 · NCT07202546
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Gilead Sciences

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 6

GlaxoSmithKline

New programs 4

Reached a new phase 0

None

Study stopped 2

  • camlipixantphase 3 · terminated Nov 20“The study has been terminated due to the decision to cease further development of camlipixant in refractory…” · NCT05600777
  • camlipixantphase 3 · terminated Nov 20“The study has been withdrawn terminated due to the decision to cease further development of camlipixant in …” · NCT07650084

Primary completion later 10

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Where they overlap

Conditions where at least two of them have programs: 44 in all. A program counts in each condition its studies name most.

ConditionGilead SciencesGlaxoSmithKlineHoffmann-La Roche
Carcinoma, Non-Small-Cell Lungall three · compare here

Gilead Sciences in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. domvanalimabphase 3
  2. Topotecanphase 3
  3. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Carcinoma, Non-Small-Cell Lung in search

GlaxoSmithKline in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. risvutatug rezetecanphase 3
  2. momelotinibphase 3
  3. neladalkibphase 3
  4. feladilimabphase 3
  5. nelistotugphase 2

and 3 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Gilead Sciences in Breast Neoplasms: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. trifluridine tipiracil drug combinationphase 2
  4. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Breast Neoplasms in search

GlaxoSmithKline in Breast Neoplasms: 3 programs

  1. nirogacestatphase 2
  2. Bevacizumabphase 2
  3. niraparibapproved, new study

Their studies: GlaxoSmithKline’s studies of Breast Neoplasms in search

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Gilead Sciences in Neoplasms: 2 programs

  1. lurbinectedinphase 3
  2. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Neoplasms in search

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Colorectal Neoplasmsall three · compare here

Gilead Sciences in Colorectal Neoplasms: 2 programs

  1. denikitugphase 2
  2. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Multiple Myelomaall three · compare here

Gilead Sciences in Multiple Myeloma: 1 program

  1. anitocabtagene autoleucelphase 3

Their studies: Gilead Sciences’ studies of Multiple Myeloma in search

GlaxoSmithKline in Multiple Myeloma: 5 programs

  1. belantamab mafodotinphase 3
  2. feladilimabphase 3
  3. nirogacestatphase 2
  4. belantamabphase 2
  5. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Multiple Myeloma in search

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Small Cell Lung Carcinomaall three · compare here

Gilead Sciences in Small Cell Lung Carcinoma: 4 programs

  1. amrubicinphase 3
  2. lurbinectedinphase 3
  3. Topotecanphase 3
  4. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Small Cell Lung Carcinoma in search

GlaxoSmithKline in Small Cell Lung Carcinoma: 2 programs

  1. risvutatug rezetecanphase 3
  2. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Small Cell Lung Carcinoma in search

Ovarian Neoplasmsall three · compare here

Gilead Sciences in Ovarian Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Ovarian Neoplasms in search

GlaxoSmithKline in Ovarian Neoplasms: 6 programs

  1. mocertatug rezetecanphase 3
  2. nirogacestatphase 2
  3. Bevacizumabphase 2
  4. ivonescimabphase 2
  5. dostarlimabapproved, new study

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Ovarian Neoplasms in search

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Gilead Sciences in Arthritis, Rheumatoid: 1 program

  1. GS-0151phase 1

Their studies: Gilead Sciences’ studies of Arthritis, Rheumatoid in search

GlaxoSmithKline in Arthritis, Rheumatoid: 1 program

  1. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Arthritis, Rheumatoid in search

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Non-alcoholic Fatty Liver Diseaseall three · compare here

Gilead Sciences in Non-alcoholic Fatty Liver Disease: 2 programs

  1. seladelparphase 3
  2. cilofexorphase 3

Their studies: Gilead Sciences’ studies of Non-alcoholic Fatty Liver Disease in search

GlaxoSmithKline in Non-alcoholic Fatty Liver Disease: 2 programs

  1. efimosfermin alfaphase 3
  2. gatuzosiranphase 2

Their studies: GlaxoSmithKline’s studies of Non-alcoholic Fatty Liver Disease in search

Hoffmann-La Roche in Non-alcoholic Fatty Liver Disease: 1 program

  1. pegozaferminphase 3

Their studies: Hoffmann-La Roche’s studies of Non-alcoholic Fatty Liver Disease in search

Endometrial Neoplasmsall three · compare here

Gilead Sciences in Endometrial Neoplasms: 1 program

  1. Topotecanphase 3

Their studies: Gilead Sciences’ studies of Endometrial Neoplasms in search

GlaxoSmithKline in Endometrial Neoplasms: 2 programs

  1. mocertatug rezetecanphase 3
  2. dostarlimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Endometrial Neoplasms in search

Hoffmann-La Roche in Endometrial Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Endometrial Neoplasms in search

Neoplasm Metastasisall three · compare here

Gilead Sciences in Neoplasm Metastasis: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Neoplasm Metastasis in search

GlaxoSmithKline in Neoplasm Metastasis: 1 program

  1. neladalkibphase 3

Their studies: GlaxoSmithKline’s studies of Neoplasm Metastasis in search

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

HIV Infections2 of 3 · compare here

Gilead Sciences in HIV Infections: 5 programs

  1. teropavimabphase 3
  2. zinlirvimabphase 3
  3. lenacapavirapproved, new study
  4. tenofovir alafenamideapproved, new study
  5. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of HIV Infections in search

GlaxoSmithKline in HIV Infections: 14 programs

  1. fostemsavirphase 3
  2. CAB ULAphase 3
  3. dezecapavirphase 2
  4. VH4524184phase 2
  5. VH3810109phase 2

and 9 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of HIV Infections in search

–
Asthma2 of 3 · compare here–

GlaxoSmithKline in Asthma: 6 programs

  1. felcorekibartphase 3
  2. norfluranephase 3
  3. HFA-152aphase 3
  4. ozureprubartphase 2
  5. HFA-152A propellantphase 1

and 1 more — sign in to see them all

Their studies: GlaxoSmithKline’s studies of Asthma in search

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

GlaxoSmithKline in Lupus Erythematosus, Systemic: 4 programs

  1. GSK5926371phase 2
  2. GSK4527363phase 1
  3. GSK4347859phase 1
  4. belimumabapproved, new study

Their studies: GlaxoSmithKline’s studies of Lupus Erythematosus, Systemic in search

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Prostatic Neoplasms2 of 3 · compare here–

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Alzheimer Disease2 of 3 · compare here–

GlaxoSmithKline in Alzheimer Disease: 1 program

  1. nivisnebartphase 2

Their studies: GlaxoSmithKline’s studies of Alzheimer Disease in search

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Lymphoma, B-Cell2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, B-Cell: 3 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3
  3. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Lymphoma, B-Cell in search

Obesity2 of 3 · compare here–

GlaxoSmithKline in Obesity: 1 program

  1. efimosfermin alfaphase 3

Their studies: GlaxoSmithKline’s studies of Obesity in search

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

Respiratory Syncytial Virus Infections2 of 3 · compare here

Gilead Sciences in Respiratory Syncytial Virus Infections: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of Respiratory Syncytial Virus Infections in search

GlaxoSmithKline in Respiratory Syncytial Virus Infections: 5 programs

  1. arexvyphase 3
  2. Adjuvanted RSVPreF3 vaccinephase 2
  3. hMPV_Y low dose vaccinephase 2
  4. RSV/hMPV_V low dose vaccinephase 2
  5. shingrixapproved, new study

Their studies: GlaxoSmithKline’s studies of Respiratory Syncytial Virus Infections in search

–
Acquired Immunodeficiency Syndrome2 of 3 · compare here

Gilead Sciences in Acquired Immunodeficiency Syndrome: 2 programs

  1. tenofovir alafenamideapproved, new study
  2. Emtricitabineapproved, new study

Their studies: Gilead Sciences’ studies of Acquired Immunodeficiency Syndrome in search

GlaxoSmithKline in Acquired Immunodeficiency Syndrome: 3 programs

  1. cabotegravirapproved, new study
  2. Dolutegravirapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Acquired Immunodeficiency Syndrome in search

–
Dermatitis, Atopic2 of 3 · compare here–

GlaxoSmithKline in Dermatitis, Atopic: 2 programs

  1. camlipixantphase 3
  2. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Dermatitis, Atopic in search

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

Influenza, Human2 of 3 · compare here–

Hoffmann-La Roche in Influenza, Human: 1 program

  1. baloxavirphase 3

Their studies: Hoffmann-La Roche’s studies of Influenza, Human in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

GlaxoSmithKline in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. felcorekibartphase 3
  2. GSK3862995Bphase 2
  3. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Pulmonary Disease, Chronic Obstructive in search

Hoffmann-La Roche in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. astegolimabphase 3
  2. RO7830698phase 2

Their studies: Hoffmann-La Roche’s studies of Pulmonary Disease, Chronic Obstructive in search

Colitis, Ulcerative2 of 3 · compare here–

GlaxoSmithKline in Colitis, Ulcerative: 2 programs

  1. aletekitugphase 2
  2. GSK4528287phase 1

Their studies: GlaxoSmithKline’s studies of Colitis, Ulcerative in search

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Diabetes Mellitus, Type 22 of 3 · compare here–

GlaxoSmithKline in Diabetes Mellitus, Type 2: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus, Type 2 in search

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

Hepatitis B, Chronic2 of 3 · compare here

Gilead Sciences in Hepatitis B, Chronic: 1 program

  1. tenofovir alafenamideapproved, new study

Their studies: Gilead Sciences’ studies of Hepatitis B, Chronic in search

GlaxoSmithKline in Hepatitis B, Chronic: 3 programs

  1. GSK-3965193phase 2
  2. bepirovirsenapproved, new study
  3. Lamivudineapproved, new study

Their studies: GlaxoSmithKline’s studies of Hepatitis B, Chronic in search

–
Liver Cirrhosis, Biliary2 of 3 · compare here

Gilead Sciences in Liver Cirrhosis, Biliary: 3 programs

  1. seladelparphase 3
  2. cilofexorphase 3
  3. PTM Cilofexor Dose Aphase 2

Their studies: Gilead Sciences’ studies of Liver Cirrhosis, Biliary in search

GlaxoSmithKline in Liver Cirrhosis, Biliary: 1 program

  1. linerixibatphase 3

Their studies: GlaxoSmithKline’s studies of Liver Cirrhosis, Biliary in search

–
Lupus Nephritis2 of 3 · compare here

Gilead Sciences in Lupus Nephritis: 1 program

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2

Their studies: Gilead Sciences’ studies of Lupus Nephritis in search

–

Hoffmann-La Roche in Lupus Nephritis: 2 programs

  1. mosunetuzumabphase 3
  2. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Lupus Nephritis in search

Lymphoma, Non-Hodgkin2 of 3 · compare here–

GlaxoSmithKline in Lymphoma, Non-Hodgkin: 1 program

  1. GSK5926371phase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma, Non-Hodgkin in search

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Nasal Polyps2 of 3 · compare here–

GlaxoSmithKline in Nasal Polyps: 2 programs

  1. felcorekibartphase 3
  2. depemokimabapproved, new study

Their studies: GlaxoSmithKline’s studies of Nasal Polyps in search

Hoffmann-La Roche in Nasal Polyps: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Nasal Polyps in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

Gilead Sciences in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. domvanalimabphase 3

Their studies: Gilead Sciences’ studies of Squamous Cell Carcinoma of Head and Neck in search

GlaxoSmithKline in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. feladilimabphase 3
  2. nelistotugphase 2

Their studies: GlaxoSmithKline’s studies of Squamous Cell Carcinoma of Head and Neck in search

–
Anemia, Hemolytic, Autoimmune2 of 3 · compare here–

GlaxoSmithKline in Anemia, Hemolytic, Autoimmune: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Anemia, Hemolytic, Autoimmune in search

Hoffmann-La Roche in Anemia, Hemolytic, Autoimmune: 1 program

  1. pegcetacoplanphase 1

Their studies: Hoffmann-La Roche’s studies of Anemia, Hemolytic, Autoimmune in search

Anemia, Sickle Cell2 of 3 · compare here–

GlaxoSmithKline in Anemia, Sickle Cell: 1 program

  1. 4CMenB vaccineapproved, new study

Their studies: GlaxoSmithKline’s studies of Anemia, Sickle Cell in search

Hoffmann-La Roche in Anemia, Sickle Cell: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Anemia, Sickle Cell in search

Bacterial Infections2 of 3 · compare here–

GlaxoSmithKline in Bacterial Infections: 1 program

  1. gepotidacinphase 3

Their studies: GlaxoSmithKline’s studies of Bacterial Infections in search

Hoffmann-La Roche in Bacterial Infections: 1 program

  1. zosurabalpinphase 1

Their studies: Hoffmann-La Roche’s studies of Bacterial Infections in search

Carcinoma, Hepatocellular2 of 3 · compare here–

GlaxoSmithKline in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: GlaxoSmithKline’s studies of Carcinoma, Hepatocellular in search

Hoffmann-La Roche in Carcinoma, Hepatocellular: 1 program

  1. codrituzumabphase 2

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Hepatocellular in search

COVID-192 of 3 · compare here

Gilead Sciences in COVID-19: 1 program

  1. obeldesivirphase 3

Their studies: Gilead Sciences’ studies of COVID-19 in search

–

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

Diabetes Mellitus2 of 3 · compare here–

GlaxoSmithKline in Diabetes Mellitus: 1 program

  1. aletekitugphase 2

Their studies: GlaxoSmithKline’s studies of Diabetes Mellitus in search

Hoffmann-La Roche in Diabetes Mellitus: 1 program

  1. enicepatidephase 3

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus in search

Kidney Diseases2 of 3 · compare here

Gilead Sciences in Kidney Diseases: 1 program

  1. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Kidney Diseases in search

GlaxoSmithKline in Kidney Diseases: 1 program

  1. GSK4771261phase 1

Their studies: GlaxoSmithKline’s studies of Kidney Diseases in search

–
Lymphoma2 of 3 · compare here–

GlaxoSmithKline in Lymphoma: 1 program

  1. isatuximabphase 2

Their studies: GlaxoSmithKline’s studies of Lymphoma in search

Hoffmann-La Roche in Lymphoma: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma in search

Lymphoma, Follicular2 of 3 · compare here

Gilead Sciences in Lymphoma, Follicular: 1 program

  1. axicabtagene ciloleucelphase 3

Their studies: Gilead Sciences’ studies of Lymphoma, Follicular in search

–

Hoffmann-La Roche in Lymphoma, Follicular: 1 program

  1. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Follicular in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here

Gilead Sciences in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. axicabtagene ciloleucelphase 3

Their studies: Gilead Sciences’ studies of Lymphoma, Large B-Cell, Diffuse in search

–

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2 of 3 · compare here

Gilead Sciences in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 1 program

  1. Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 2

Their studies: Gilead Sciences’ studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

–

Hoffmann-La Roche in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 1 program

  1. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Stomach Neoplasms2 of 3 · compare here

Gilead Sciences in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationphase 2

Their studies: Gilead Sciences’ studies of Stomach Neoplasms in search

–

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

Triple Negative Breast Neoplasms2 of 3 · compare here

Gilead Sciences in Triple Negative Breast Neoplasms: 1 program

  1. sacituzumab govitecanapproved, new study

Their studies: Gilead Sciences’ studies of Triple Negative Breast Neoplasms in search

GlaxoSmithKline in Triple Negative Breast Neoplasms: 1 program

  1. ivonescimabphase 2

Their studies: GlaxoSmithKline’s studies of Triple Negative Breast Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Gilead Sciences 16 of 32 · GlaxoSmithKline 65 of 88 · Hoffmann-La Roche 39 of 80 programs (46 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (GlaxoSmithKline: 17, Hoffmann-La Roche: 25).